Flash Finance

Dishman Carbogen Amcis LimitedDCALCorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹149.83
MCap ₹2,349 Cr
Dishman Carbogen Amcis Limited — Stock analysis & AI research Dishman Carbogen Amcis Limited — Seasonality — best & worst months Dishman Carbogen Amcis Limited — Technical indicators & charts Dishman Carbogen Amcis Limited — Technical setup — score, trend, support & resistance Dishman Carbogen Amcis Limited — Live exchange announcements
📋 Stocks Below Book Value 📈 MACD Bullish Crossover📈 Multi-Timeframe Bearish Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹57 Cr
Sales · Jun 2026
-9.2% YoY
₹-12 Cr
Operating Profit · Jun 2026
-444.6% YoY
-20.7%
OPM % · Jun 2026
-476.4% YoY
₹-24 Cr
Net Profit · Jun 2026
-995.5% YoY
₹-1.52
EPS · Jun 2026
-994.1% YoY

📝 Dishman Carbogen Amcis Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Dishman Carbogen Amcis Limited reported revenue of ₹57 crore for the quarter ended June 2026 (Q1 FY27), down 9.2% from ₹63 crore in the same quarter last year, and down 16.9% sequentially over the March 2026 quarter.

The company reported a net loss of ₹24 crore, against a net profit of ₹3 crore in the same quarter last year. Earnings per share (EPS) came in at ₹-1.52.

Operating profit stood at ₹-12 crore — an operating margin (OPM) of -20.7%, compared with 5.5% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Dishman Carbogen Amcis Limited posted revenue of ₹232 crore, a decline of 42.1% over FY25, with a net loss of ₹38 crore.

On a trailing-twelve-month (TTM) basis, revenue stands at ₹226 crore with a net loss of ₹65 crore.

Valuation snapshot

At the current price of ₹149.83, DCAL has a market capitalisation of ₹2,349 crore.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 19th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 59.32%, foreign institutional investors (FIIs) 6.86%, domestic institutional investors (DIIs) 2.07%, public shareholders 31.75% of Dishman Carbogen Amcis Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹2,349 Cr
Current Price ?
₹149.8
P/E ?
N/A
Industry P/E ?
37.20
P/B ?
0.61
P/S ?
10.40
P/FCF ?
123.64
Enterprise Value ?
₹2,983 Cr
EV/EBITDA ?
-300.41
PEG ?
N/A
Earnings Yield ?
-2.4%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹226 Cr
OPM ?
-4.4%
Profit after tax (TTM) ?
₹-65 Cr
EPS (TTM) ?
₹-4.14
ROCE ?
1.0%
ROE ?
-1.7%
ROA ?
-1.3%
Growth
Sales — latest qtr ?
₹57 Cr
PAT — latest qtr ?
₹-24 Cr
YoY qtr sales growth ?
-9.2%
YoY qtr profit growth ?
-995.5%
Sales growth (3y) ?
-17%
Sales growth (5y) ?
3%
Profit growth (3y) ?
10%
Profit growth (5y) ?
13%
Financial Health
Debt ?
₹634 Cr
Debt to Equity ?
0.16
Interest Coverage ?
-0.7
Current Ratio ?
N/A
Ownership
Promoter holding ?
59.32%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
-21.7%
Return 6 months ?
-11.1%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 7811370608765510393971066360406957 -9.2% -16.9%
Operating Profit -36-5-33631513232134-41-12 -444.6% -1306.1%
Other Income 121514361371224-85371172919 -49.5% -34.5%
Interest 151718171731161618212021242222 +7.2% -1.9%
Depreciation 32325252685161616161616151515 -6.7% +1.5%
Profit Before Tax -10-19-33-9-27-49-65-19-114-21-35-7-32 -869.4% -323.8%
Net Profit -7-10-21-6-18-70-314-13-73-14-23-4-24 -995.5% -450.9%
EPS -0.42-0.65-1.36-0.37-1.16-1.98-0.220.91-0.85-0.470.17-0.87-1.48-0.28-1.52 -994.1% -442.9%
OPM % -4.1% 5.6% -7.2% -4.9% 3.7% 9.6% 14.4% 14.4% 23.7% 19.3% 5.5% 7.3% -8.8% 1.4% -20.7% -476.4% -1578.6%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹400 Cr ₹232 Cr ₹226 Cr -42.1%
Operating Profit ₹72 Cr ₹5 Cr ₹-10 Cr -92.6%
OPM % 17.95% 2.30% -4.40% -87.2%
NPM % -2.47% -16.58% -28.78% -571.3%
Other Income ₹33 Cr ₹85 Cr ₹66 Cr +156.3%
Depreciation ₹65 Cr ₹63 Cr ₹61 Cr -4.0%
Interest ₹70 Cr ₹87 Cr ₹88 Cr +22.9%
EBIT ₹7 Cr ₹-57 Cr ₹-71 Cr -968.7%
PBT ₹-31 Cr ₹-59 Cr ₹-95 Cr -92.2%
Tax ₹-2 Cr — ₹-8 Cr —
Net Profit ₹-10 Cr ₹-38 Cr ₹-65 Cr -289.1%
EPS ₹-0.63 ₹-2.46 ₹-4.15 -290.5%
Material Cost ₹32 Cr — ₹15 Cr —
Employee Cost ₹23 Cr — ₹21 Cr —
Extraordinary Items — — ₹-2 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 31313131 +0.0%
Reserves 4,0834,0213,9993,851 -3.7%
Borrowings 593536686634 -7.6%
Other Liabilities 473488405610 +50.6%
Total Liabilities 5,1815,0775,1225,126 +0.1%
Fixed Assets 1,3821,4161,4011,372 -2.1%
CWIP 143744123 -43.9%
Investments 2,9132,8482,8412,844 +0.1%
Other Assets 743739840887 +5.6%
Total Assets 5,1815,0775,1225,126 +0.1%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity -53245646 -17.9%
Cash from Investing Activity 4197-8022 +127.5%
Cash from Financing Activity 1-13188-120 -236.4%
Net Cash Flow -11-1064-52 -181.2%
Free Cash Flow -175-12219 +850.0%
CFO/OP -556%373%81%914% +1028.4%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 133205160269 +68.1%
Inventory Days 3895343741,440 +285.0%
Days Payable 182365201699 +247.8%
Cash Conversion Cycle 3403743331,010 +203.3%
Working Capital Days -123-62-74-342 -362.2%
ROCE % -1%-1%1%1% +0.0%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 % Chg
Promoters 59.32%59.32%59.32%59.32%59.32% +0.0%
FIIs 9.94%8.07%7.66%7.45%6.86% -7.9%
DIIs 1.27%1.37%1.27%1.63%2.07% +27.0%
Public 29.48%31.23%31.75%31.60%31.75% +0.5%
No. of Shareholders 49,74449,45548,48149,00949,430 +0.9%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 AKUMS Akums Drugs ₹784.55 12,012 41.2 4,502 293 12.6% 6.5% 5.9% -25.5% 13.9% 56.1%
2 STAR Strides Pharma ₹1,085.00 10,001 26.7 3,636 389 25.4% 10.7% -20.4% 99.0% 11.2% 50.0%
3 BLUEJET Blue Jet ₹565.05 9,802 36.9 884 265 36.3% 30.0% 8.0% 0.7% -17.5% -14.3%
4 AARTIPHARM Aarti Pharmalabs ₹828.30 7,511 36.1 1,957 208 22.0% 10.6% 1.5% -26.9% 42.4% 39.2%
5 SUPRIYA Supriya Lifescience ₹870.30 7,004 35.3 873 198 33.2% 22.7% 18.9% 11.1% 30.8% -30.9%
6 INNOVACAP Innova Captab ₹1,199.30 6,863 13.8 5,779 497 14.6% 8.6% 355.1% 277.4% 33.9% 42.3%
7 MOREPENLAB Morepen Laboratories ₹123.35 6,759 48.0 1,951 141 9.4% 7.2% -0.3% -18.3% 34.1% 394.0%
8 IOLCP IOL Chemicals ₹201.19 5,905 35.2 2,523 168 12.3% 6.7% 11.5% 36.6% 37.1% 89.8%
9 FDC FDC ₹350.20 5,702 19.5 2,191 291 15.3% 13.3% 3.0% 4.8% 3.0% 9.5%
10 NOVARTIND Novartis India ₹2,257.80 5,575 57.0 371 97 27.6% 26.2% -0.3% -6.9% 18.2% 14.3%
11 ORCHPHARMA Orchid Pharma ₹1,058.75 5,370 236.9 812 22 5.1% 2.7% -11.9% -76.4% 0.2% 25.4%
12 RPGLIFE RPG Life ₹2,865.90 4,740 39.7 735 120 21.1% 16.3% 8.4% -36.9% 15.8% 16.3%
13 ZOTA Zota Health ₹1,232.70 4,269 — 609 -104 0.6% -17.1% 84.6% -29.8% 66.9% -213.9%
14 GUFICBIO Gufic Biosciences ₹419.85 4,210 57.3 974 74 16.9% 7.6% 14.7% -9.1% 14.9% 86.0%
15 UNICHEMLAB Unichem Laboratories ₹526.70 3,708 12.2 2,308 305 9.9% 13.2% 6.2% 74.1% 20.1% 496.1%
16 INDSWFTLAB Ind-Swift Laboratories ₹374.00 3,252 55.4 665 57 9.0% 8.6% 235.3% 10.1% 32.3% -88.7%
17 ADVENZYMES Advanced Enzyme ₹293.25 3,249 19.8 750 172 29.8% 22.9% 17.1% 29.6% 2.1% -4.6%
18 SOLARA Solara Active ₹667.00 3,218 85.6 1,535 37 15.2% 2.4% 6.6% -1470.4% 33.1% 381.8%
19 DCAL Dishman Carbogen ₹162.08 2,541 157.6 2,902 16 16.7% 0.6% 8.1% 2655.7% -4.3% -351.7%
20 INDOCO Indoco Remedies ₹254.59 2,347 n/m 1,872 3 8.8% 0.2% 10.7% -26.5% 6.5% 280.0%
21 PANACEABIO Panacea Biotec ₹368.55 2,257 — 673 -9 0.3% -1.3% 14.4% 17.9% 19.7% -44.4%
22 REMUS Remus Pharma. ₹1,911.30 2,252 91.1 94 25 31.7% 26.7% — — 13.3% 21.4%
23 SAKAR Sakar Healthcare ₹987.40 2,167 61.0 272 36 28.5% 13.3% 41.9% 71.8% 38.4% 120.2%
24 JAGSNPHARM Jagsonpal Pharmaceuticals ₹227.53 1,501 33.3 294 45 20.7% 15.4% 6.9% -22.2% 8.5% 20.4%
25 KOPRAN Kopran ₹281.55 1,361 54.5 700 25 8.7% 3.6% -96.0% -97.6% 13.9% -10.0%
❓ Frequently asked questions
What was Dishman Carbogen Amcis Limited's revenue in Q1 FY27?
Dishman Carbogen Amcis Limited reported revenue of ₹57 crore for the quarter ended June 2026 (Q1 FY27), down 9.2% from ₹63 crore in the same quarter last year, and down 16.9% sequentially over the March 2026 quarter.
What was Dishman Carbogen Amcis Limited's net profit in Q1 FY27?
The company reported a net loss of ₹24 crore, against a net profit of ₹3 crore in the same quarter last year. Earnings per share (EPS) came in at ₹-1.52.
What is DCAL's market capitalisation and P/E ratio?
At the current price of ₹149.83, DCAL has a market capitalisation of ₹2,349 crore.
Who owns Dishman Carbogen Amcis Limited? (shareholding pattern)
As of Jun 2026, promoters held 59.32%, foreign institutional investors (FIIs) 6.86%, domestic institutional investors (DIIs) 2.07%, public shareholders 31.75% of Dishman Carbogen Amcis Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI